Initial surgical management of sporadic medullary thyroid cancer: Guidelines based optimal care - A systematic review.
cancer
guidelines
medullary
sporadic
thyroid
Journal
Clinical endocrinology
ISSN: 1365-2265
Titre abrégé: Clin Endocrinol (Oxf)
Pays: England
ID NLM: 0346653
Informations de publication
Date de publication:
12 Mar 2024
12 Mar 2024
Historique:
revised:
02
01
2024
received:
19
10
2023
accepted:
22
02
2024
medline:
13
3
2024
pubmed:
13
3
2024
entrez:
13
3
2024
Statut:
aheadofprint
Résumé
Medullary thyroid carcinoma (MTC) is a rare neuroendocrine tumor from parafollicular cells that produce calcitonin (Ct). Despite several existing guidelines for the surgical management of sporadic MTC (sMTC), optimal initial surgical management of the thyroid, the central and the lateral neck remains a matter of debate. A systematic review in PubMed and Scopus for current guidelines addressing the surgical management of sMTC and its referenced citations was conducted as per the PRISMA guidelines. Two-hundred and one articles were identified, of which 7 met the inclusion criteria. Overall, guidelines vary significantly in their recommendations for the surgical management of sMTC. Only one guideline recommended partial thyroidectomy for limited disease, but the possibility to avoid completion thyroidectomy in selected cases is acknowledged in 42% (3/7) of the remaining guidelines. The majority of guidelines (71.4%; 5/7) recommended prophylactic central neck dissection (CND) for all patients while the remaining two guidelines recommended CND based on Ct level and tumor size. The role of prophylactic lateral neck dissection based on preoperative Ct levels was recommended by 42% (3/7) of guidelines. Overall, these guidelines are based on low-quality evidence, mostly single-center retrospective series, some of which are over 20 years old. Current surgical management guidelines of sMTC should be revised, and ought to be based on updated data challenging current recommendations, which are based on historic, low-quality evidence. Partial thyroidectomy may become a viable option for small, limited tumors. Prospective, multi-center studies may be useful to conclude whether prophylactic ND is necessary in all sMTC patients.
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 John Wiley & Sons Ltd.
Références
Wells SA, Asa SL, Dralle H, et al. Revised American thyroid association guidelines for the management of medullary thyroid carcinoma. Thyroid. 2015;25(6):567-610. doi:10.1089/thy.2014.0335
Poorten VV, Hens G, Delaere P. Thyroid cancer in children and adolescents. Curr Opinion Otolaryngol Head Neck Surg. 2013;21(2):135-142. doi:10.1097/MOO.0b013e32835e15d9
Romei C, Casella F, Tacito A, et al. New insights in the molecular signature of advanced medullary thyroid cancer: evidence of a bad outcome of cases with double RET mutations. J Med Genet. 2016;53(11):729-734. doi:10.1136/jmedgenet-2016-103833
Dralle H, Machens A. Surgical management of the lateral neck compartment for metastatic thyroid cancer. Curr Opin Oncol. 2013;25(1):20-26. doi:10.1097/CCO.0b013e328359ff1f
Haddad RI, Bischoff L, Ball D, et al. Thyroid carcinoma, version 2.2022, NCCN clinical practice guidelines in oncology. J Nat Compreh Cancer Net. 2022;20(8):925-951. doi:10.6004/jnccn.2022.0040
Ito Y, Onoda N, Okamoto T. The revised clinical practice guidelines on the management of thyroid tumors by the Japan associations of endocrine surgeons: core questions and recommendations for treatments of thyroid cancer. Endocr J. 2020;67(7):669-717. doi:10.1507/endocrj.EJ20-0025
Maia AL, Siqueira DR, Kulcsar MAV, Tincani AJ, Mazeto GMFS, Maciel LMZ. Diagnóstico, tratamento e seguimento do carcinoma medular de tireoide: recomendações do departamento de tireoide da sociedade brasileira de endocrinologia e metabologia. Arqu Brasileiros de Endocrinol Metabol. 2014;58(7):667-700. doi:10.1590/0004-2730000003427
Jarząb B, Dedecjus M, Słowińska-Klencka D, et al. Rekomendacje polskich towarzystw naukowych „diagnostyka I leczenie raka tarczycy”. aktualizacja na rok 2018. Endokrynol Pol. 2018;69(1):34-74. doi:10.5603/EP.2018.0014
Filetti S, Durante C, Hartl D, et al. Thyroid cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2019;30(12):1856-1883. doi:10.1093/annonc/mdz400
Mitchell AL, Gandhi A, Scott-Coombes D, Perros P. Management of thyroid cancer: United Kingdom national multidisciplinary guidelines. J Laryngol Otol. 2016;130(S2):S150-S160. doi:10.1017/S0022215116000578
Yang B, Niu G, Li X, Ma F, Ma Y, Hu S. Lobectomy may be more appropriate for patients with early-stage medullary thyroid cancer older than 60 years old. Front Endocrinol (Lausanne). 2022;13:1015319. doi:10.3389/fendo.2022.1015319
Liang W, Shi J, Zhang H, et al. Total thyroidectomy vs thyroid lobectomy for localized medullary thyroid cancer in adults: a propensity-matched survival analysis. Surgery. 2022;172(5):1385-1391. doi:10.1016/j.surg.2022.06.023
Pillarisetty VG, Katz SC, Ghossein RA, Tuttle RM, Shaha AR. Micromedullary thyroid cancer: how micro is truly micro. Ann Surg Oncol. 2009;16(10):2875-2881. doi:10.1245/s10434-009-0595-1
Juez LD, Mercader E, Amunategui I, et al. Extension of prophylactic surgery in medullary thyroid carcinoma. differences between sporadic and hereditary tumours according to calcitonin levels and lymph node involvement. World J Surg. 2022;46(4):820-828. doi:10.1007/s00268-022-06448-6
Spanheimer PM, Ganly I, Chou JF, et al. Prophylactic lateral neck dissection for medullary thyroid carcinoma is not associated with improved survival. Ann Surg Oncol. 2021;28(11):6572-6579. doi:10.1245/s10434-021-09683-8
Saad MF, Ordonez NG, Rashid RK, et al. Medullary carcinoma of the thyroid. A study of the clinical features and prognostic factors in 161 patients. Medicine. 1984;63(6):319-342.
Moley JF, DeBenedetti MK. Patterns of nodal metastases in palpable medullary thyroid carcinoma. Ann Surg. 1999;229(6):880. doi:10.1097/00000658-199906000-00016
Kebebew E, Ituarte PHG, Siperstein AE, Duh QY, Clark OH. Medullary thyroid carcinoma. Cancer. 2000;88(5):1139-1148. doi:10.1002/(SICI)1097-0142(20000301)88:5<1139::AID-CNCR26>3.0.CO;2-Z
Miyauchi A, Matsuzuka F, Hirai K, et al. Unilateral surgery supported by germline RET oncogene mutation analysis in patients with sporadic medullary thyroid carcinoma. World J Surg. 2000;24(11):1367-1372. doi:10.1007/s002680010226
Kaserer K, Scheuba C, Neuhold N, et al. Sporadic versus familial medullary thyroid microcarcinoma. Am J Surg Pathol. 2001;25(10):1245-1251. doi:10.1097/00000478-200110000-00004
Miyauchi A, Matsuzuka F, Hirai K, et al. Prospective trial of unilateral surgery for nonhereditary medullary thyroid carcinoma in patients without germline RET mutations. World J Surg. 2002;26(8):1023-1028. doi:10.1007/s00268-002-6665-1
Greenblatt DY, Mack E, Chen H, Elson D. Initial lymph node dissection increases cure rates in patients with medullary thyroid cancer. Asian J Surg. 2007;30(2):108-112. doi:10.1016/S1015-9584(09)60141-X
Grozinsky-Glasberg S, Benbassat CA, Tsvetov G, et al. Medullary thyroid cancer: a retrospective analysis of a cohort treated at a single tertiary care center between 1970 and 2005. Thyroid. 2007;17(6):549-556. doi:10.1089/thy.2006.0229
Machens A, Hauptmann S, Dralle H. Increased risk of lymph node metastasis in multifocal hereditary and sporadic medullary thyroid cancer. World J Surg. 2007;31(10):1960-1965. doi:10.1007/s00268-007-9185-1
Ito Y, Miyauchi A, Yabuta T, et al. Alternative surgical strategies and favorable outcomes in patients with medullary thyroid carcinoma in Japan: experience of a single institution. World J Surg. 2009;33(1):58-66. doi:10.1007/s00268-008-9795-2
Lupone G, Antonino A, Rosato A, et al. Surgical strategy for the treatment of sporadic medullary thyroid carcinoma: our experience. G Chir. 2012;33(11-12):395-399.
Dralle H, Scheumann GFW, Proye C, et al. The value of lymph node dissection in hereditary medullary thyroid carcinoma: a retrospective, European, multicentre study. J Intern Med. 1995;238(4):357-361. doi:10.1111/j.1365-2796.1995.tb01210.x
Modigliani E, Cohen R, Campos JM, et al. Prognostic factors for survival and for biochemical cure in medullary thyroid carcinoma: results in 899 patients. Clin Endocrinol. 1998;48(3):265-273. doi:10.1046/j.1365-2265.1998.00392.x
Franc S, Niccoli-Sire P, Cohen R, et al. Complete surgical lymph node resection does not prevent authentic recurrences of medullary thyroid carcinoma. Clin Endocrinol. 2001;55(3):403-409. doi:10.1046/j.1365-2265.2001.01339.x
Weber T, Schilling T, Frank-Raue K, et al. Impact of modified radical neck dissection on biochemical cure in medullary thyroid carcinomas. Surgery. 2001;130(6):1044-1049. doi:10.1067/msy.2001.118380a
Giraudet AL, Vanel D, Leboulleux S, et al. Imaging medullary thyroid carcinoma with persistent elevated calcitonin levels. J Clin Endocrino Metabol. 2007;92(11):4185-4190. doi:10.1210/jc.2007-1211
Machens A, Hauptmann S, Dralle H. Prediction of lateral lymph node metastases in medullary thyroid cancer. Br J Surg. 2008;95(5):586-591. doi:10.1002/bjs.6075
Tavares MR, Michaluart P, Montenegro F, et al. Skip metastases in medullary thyroid carcinoma: a single-center experience. Surg Today. 2008;38(6):499. doi:10.1007/s00595-007-3664-8
Machens A, Dralle H. Biomarker-Based risk stratification for previously untreated medullary thyroid cancer. J Clin Endocrinol Metabol. 2010;95(6):2655-2663. doi:10.1210/jc.2009-2368
Machens A, Dralle H. Surgical treatment of medullary thyroid cancer. Recent Res Cancer Res. 2015;204:187-205. doi:10.1007/978-3-319-22542-5_9
Zhang Q, Xin X, Wang L. A bibliometric analysis of 8271 publications on thyroid nodules from 2000 to 2021. Front Endocrinol (Lausanne). 2022;13:845776. doi:10.3389/fendo.2022.845776
Frisco NA, Gunn AH, Wang F, Stang MT, Kazaure HS, Scheri RP. Guideline adherence and practice patterns in the management of medullary thyroid cancer. J Surg Res. 2023;281:214-222. doi:10.1016/j.jss.2022.08.039
McMullin JL, Sharma J, Gillespie T, Patel SG, Weber CJ, Saunders ND. Improved adherence to ATA medullary thyroid cancer treatment guidelines. Ann Surg Oncol. 2023;30(12):7165-7171. doi:10.1245/s10434-022-12734-3
Chang EHE, Lutfi W, Feinglass J, Reiher AE, Moo-Young T, Bhayani MK. National trends in the surgical treatment of non-advanced medullary thyroid cancer (MTC): an evaluation of adherence with the 2009 American thyroid association guidelines. World J Surg. 2016;40(12):2930-2940. doi:10.1007/s00268-016-3643-6
Verbeek HHG, Meijer JAA, Zandee WT, et al. Fewer cancer reoperations for medullary thyroid cancer after initial surgery according to ATA guidelines. Ann Surg Oncol. 2015;22(4):1207-1213. doi:10.1245/s10434-014-4115-6
Cho SW. A high frequency of lobectomy instead of total thyroidectomy to treat medullary thyroid cancer in korea: data from the Korean national health insurance service. Endocrinol Metab. 2020;35(4):784-785. doi:10.3803/EnM.2020.408
Essig GF, Porter K, Schneider D, et al. Multifocality in sporadic medullary thyroid carcinoma: an international multicenter study. Thyroid. 2016;26(11):1563-1572. doi:10.1089/thy.2016.0255
Pilaete K, Delaere P, Decallonne B, et al. Medullary thyroid cancer: prognostic factors for survival and recurrence, recommendations for the extent of lymph node dissection and for surgical therapy in recurrent disease. B-ENT. 2012;8(2):113-121.
Pena I, Clayman GL, Grubbs EG, et al. Management of the lateral neck compartment in patients with sporadic medullary thyroid cancer. Head Neck. 2018;40(1):79-85. doi:10.1002/hed.24969
Ito Y, Miyauchi A, Kihara M, Higashiiyama T, Fukushima M, Miya A. Static prognostic factors and appropriate surgical designs for patients with medullary thyroid carcinoma: the second report from a Single-Institution study in Japan. World J Surg. 2018;42(12):3954-3966. doi:10.1007/s00268-018-4738-z
Moura MM, Cavaco BM, Pinto AE, et al. Correlation of RET somatic mutations with clinicopathological features in sporadic medullary thyroid carcinomas. Br J Cancer. 2009;100(11):1777-1783. doi:10.1038/sj.bjc.6605056
Mian C, Pennelli G, Barollo S, et al. Combined RET and Ki-67 assessment in sporadic medullary thyroid carcinoma: a useful tool for patient risk stratification. Eur J Endocrinol. 2011;164(6):971-976. doi:10.1530/EJE-11-0079
Contrera KJ, Gule-Monroe MK, Hu MI, et al. Neoadjuvant selective RET inhibitor for medullary thyroid cancer: a case series. Thyroid. 2023;33(1):129-132. doi:10.1089/thy.2022.0506